Acta Cryst.(2002). E58, o1169±o1171 DOI: 10.1107/S1600536802017683 Peeters and Blaton C14H21ClN3O3+C4H5O6ÿH2O
o1169
organic papers
Acta Crystallographica Section E
Structure Reports
Online
ISSN 1600-5368
(+)-(3
S
,4
R
)-Norcisapride hydrogen
(2
R
,3
R
)-tartrate monohydrate
Oswald M. Peeters* and Norbert M. Blaton
Laboratorium voor Analytische Chemie en Medicinale Fysicochemie, Faculteit Farmaceutische Wetenschappen, Katholieke Universiteit Leuven, Van Evenstraat 4, B-3000 Leuven, Belgium
Correspondence e-mail:
oswald.peeters@pharm.kuleuven.ac.be
Key indicators
Single-crystal X-ray study
T= 293 K
Mean(C±C) = 0.004 AÊ
Rfactor = 0.037
wRfactor = 0.107 Data-to-parameter ratio = 8.0
For details of how these key indicators were automatically derived from the article, see http://journals.iucr.org/e.
#2002 International Union of Crystallography Printed in Great Britain ± all rights reserved
The title compound, (+)-(3S,4R)-cis
-4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-1-ium-4-yl)benzamide
hydrogen (2R,3R)-dihydroxybutanedioate monohydrate,
C14H21ClN3O3+C4H5O6ÿH2O, is the (+)-tartrate salt of
(+)-norcisapride. It has been found that (+)-norcisapride has both 5-HT3 antagonistic and 5-HT4 agonistic properties and is further substantially devoid of central nervous system
effects. An intramolecular NÐH O hydrogen bond forces
the amido group to be roughly coplanar with the substituted benzene ring. A three-dimensional network of hydrogen bonds is formed in the crystal. The absolute con®guration of (+)-norcisapride is 3S,4R.
Comment
The title compound, (I), is the (+)-tartrate salt of the (+)-enantiomer of norcisapride.
Racemic norcisapride is the principal metabolite of racemic
cisapride, a widely used gastrokinetic drug (Meuldermanset
al., 1988). The metabolization occurs mainly via the
cyto-chrome P-450 isoenzyme CYP3A4 (Bohets et al., 2000).
Certain therapeutic agents (e.g.ketoconazole) that inhibit the metabolic pathway of cisapride can give rise to undesirably high cisapride blood levels that may cause side effects.
It has been discovered that (ÿ)-norcisapride is a potent
drug for the treatment of gastro-oesophageal re¯ux disease, while substantially reducing adverse effects associated with the administration of racemic cisapride (McCullough & Aberg, 1998). It has also been found that (+)-norcisapride has both 5-HT3 antagonistic and 5-HT4 agonistic properties and is further substantially devoid of central nervous system effects (Heykantset al., 1999).
To contribute to a better understanding of the mechanism of action of (ÿ)- and (+)-norcisapride, the crystal structure and absolute con®guration of the title compound was deter-mined.
The absolute con®guration of the (+)-norcisapride moiety is 3S,4Rin view of the fact that the Flack (1983) parameter for
this con®guration isÿ0.01 (2) and that the known
con®gura-tion 2R,3Rfor (+)-tartrate is obtained. As in the structures of
organic papers
o1170
Peeters and Blaton C14H21ClN3O3+C4H5O6ÿH2O Acta Cryst.(2002). E58, o1169±o1171cisapride (Collinet al., 1989) and cisapride tartrate (Peeterset
al., 1997), an intramolecular hydrogen bond between the
amido N atom and the O atom of theo-methoxy substituent
(Table 1) forces the amido moiety and the substituted benzene ring to be roughly coplanar [dihedral angle between the two
least-squares planes: 10.8 (1)]. The C-atom chain of the
hydrogen tartrate ion is in an extended conformation, with the
hydroxyl O atoms having aÿscconformation with respect to
one another. The hydrogen bonds listed in Table 1 form a three-dimensional network in the crystal.
Experimental
The title compound was obtained from the Janssen Research Foun-dation, Beerse, Belgium. The synthesis has been described by Heykantset al.(1999). Single crystals were grown by slow evapora-tion from a soluevapora-tion in methanol±water.
Crystal data
C14H21ClN3O3+C4H5O6ÿH2O
Mr= 481.89 Monoclinic,P21
a= 7.6086 (4) AÊ
b= 10.664 (1) AÊ
c= 14.0482 (6) AÊ = 93.980 (6)
V= 1137.1 (1) AÊ3
Z= 2
Dx= 1.407 Mg mÿ3 CuKradiation Cell parameters from 39
re¯ections = 10.8±28.0 = 2.01 mmÿ1
T= 293 K Block, colourless 0.450.300.26 mm
Data collection
SiemensP4 four-circle diffractometer !/2scans
Absorption correction: scan (XEMP; Siemens, 1989)
Tmin= 0.325,Tmax= 0.593
2935 measured re¯ections 2350 independent re¯ections 2280 re¯ections withF2> 2(F2)
Rint= 0.033
max= 69.0
h=ÿ1!8
k=ÿ1!12
l=ÿ17!17 3 standard re¯ections
every 100 re¯ections intensity decay: none
Re®nement
Re®nement onF2
R[F2> 2(F2)] = 0.037
wR(F2) = 0.107
S= 1.06 2350 re¯ections 295 parameters
H-atom parameters constrained
w= 1/[2(F
o2) + (0.069P)2 + 0.2043P]
whereP= (Fo2+ 2Fc2)/3
(/)max< 0.001
max= 0.21 e AÊÿ3
min=ÿ0.26 e AÊÿ3
Extinction correction:SHELXL97 Extinction coef®cient: 0.026 (2) Absolute structure: Flack (1983),
220 Friedel pairs Flack parameter =ÿ0.01 (2)
Table 1
Hydrogen-bonding geometry (AÊ,).
DÐH A DÐH H A D A DÐH A
N9ÐH9 O18 0.86 1.97 2.643 (3) 134
O26ÐH26 O22 0.82 2.03 2.545 (4) 120
O28ÐH28 O11 0.82 1.97 2.776 (3) 167
O32ÐH32A O26 0.85 1.96 2.764 (5) 158
N1ÐH1A O11i 0.90 2.21 2.953 (3) 140
N1ÐH1B O22ii 0.90 1.86 2.728 (4) 161
N20ÐH20A O23iii 0.86 2.16 2.955 (4) 155
N20ÐH20B O31iv 0.86 2.41 2.970 (4) 123
O30ÐH30 O23v 0.82 1.72 2.535 (3) 171
O32ÐH32B O28vi 0.85 2.34 3.107 (5) 150
Symmetry codes: (i) 1x;y;z; (ii) 2ÿx;1
2y;1ÿz; (iii) 1ÿx;12y;2ÿz; (iv) ÿx;1
2y;2ÿz; (v)xÿ1;y;z; (vi) 1ÿx;yÿ12;1ÿz.
The positions of the H atoms of the water molecule were obtained with the programHYDROGEN(Nardelli, 1999). Those of the OH and methyl groups were found from a circular difference Fourier synthesis. The remaining H atoms were calculated geometrically. All H atoms were included in the re®nement, but constrained to ride on their parent atoms. The isotropic displacement parameters of the H atoms were ®xed at 1.25Ueqof their parent atoms.
Data collection: XSCANS (Siemens, 1996); cell re®nement:
XSCANS; data reduction: XSCANS; program(s) used to solve structure:SIR92 (Altomareet al., 1994); program(s) used to re®ne structure: SHELXL97 (Sheldrick, 1997); molecular graphics:
DIAMOND (Bergerhoff, 1996); software used to prepare material for publication:PARST(Nardelli, 1983),PLATON(Spek, 1998) and
WinGX(Farrugia, 1999).
References
Altomare, A., Cascarano, G., Giacovazzo, C., Guagliardi, A., Burla, M. C., Polidori, G. & Camalli, M. (1994).J. Appl. Cryst.27, 435.
Bergerhoff, G. (1996). DIAMOND. Gerhard-Domagk-Straûe 1, Bonn, Germany.
Bohets, H., Lavrijsen, K., Hendrickx, J., Van Houdt, J., Van Genechten, V., Verboven, P., Meuldermans, W. & Heykants, J. (2000).Br. J. Pharmacol.129, 1655±1667.
Collin, S., Vercauteren, D. P., Evrard, G., Durant, F., Tollenaere, J. P. & Moereels, H. (1989).J. Mol. Struct.214, 159±175.
Farrugia, L. J. (1999).J. Appl. Cryst.32, 837±838. Flack, H. D. (1983).Acta Cryst.A39, 876±881.
Heykants, J., Megens, A., Meuldermans, W. & Schuurkes, J. (1999). Patent No. WO9902496.
McCullough, J. & Aberg, A. (1998). Patent No. WO9640133.
Meuldermans, W., Vanpeer A., Hendrickx, J., Lauwers, W., Swysen, E., Bockx, M., Woestenborghs, R. & Heykants, J. (1988).Drug Metab. Dispos.16, 403± 409.
Figure 1
Nardelli, M. (1983).Comput. Chem.7, 95±98. Nardelli, M. (1999).J. Appl. Cryst.32, 563±571.
Peeters, O. M., Blaton, N. M. & De Ranter, C. J. (1997).Acta Cryst.C53, 597± 599.
Sheldrick, G. M. (1997).SHELXL97. University of GoÈttingen, Germany.
Siemens (1989).XEMP.Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
Siemens (1996).XSCANS. Version 2.2. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
Spek, A. L. (1998).PLATON.University of Utrecht, The Netherlands.
supporting information
sup-1
Acta Cryst. (2002). E58, o1169–o1171
supporting information
Acta Cryst. (2002). E58, o1169–o1171 [doi:10.1107/S1600536802017683]
(+)-(3
S
,4
R
)-Norcisapride hydrogen (2
R
,3
R
)-tartrate monohydrate
Oswald M. Peeters and Norbert M. Blaton
S1. Comment
The title compound, (I), is the (+)-tartrate salt of the (+)-enantiomer of norcisapride.
Racemic norcisapride is the principal metabolite of racemic cisapride, a widely used gastrokinetic drug (Meuldermans
et al., 1988). The metabolization occurs mainly via the cytochrome P-450 isoenzyme CYP3A4 (Bohets et al., 2000). Certain therapeutic agents (e.g. ketoconazole) that inhibit the metabolic pathway of cisapride can give rise to undesirably high cisapride blood levels that may cause side effects.
It has been discovered that (-)-norcisapride is a potent drug for the treatment of gastro-esophageal reflux disease while substantially reducing adverse effects associated with the administration of racemic cisapride (McCullough & Aberg, 1998). It has also been found that (+)-norcisapride has both 5-HT3 antagonistic and 5-HT4 agonistic properties and is further substantially devoid of central nervous system effects (Heykants et al., 1999).
To contribute to a better understanding of the mechanism of action of the (-)- and (+)-norcisapride, the crystal structure and absolute configuration of the title compound was determined.
The absolute configuration of the (+)-norcisapride moiety is 3S,4R in view of the fact that the Flack (1983) parameter for this configuration is −0.01 (2) and that the known configuration 2R,3R for (+)-tartrate is obtained. As in the structures of cisapride (Collin et al., 1989) and cisapride tartrate (Peeters et al., 1997) an intramolecular hydrogen bond between the amidic N atom and the O atom of the o-methoxy substituent (Table 1) forces the amido moiety and the substituted benzene ring to be roughly coplanar [dihedral angle between the two least-squares planes: 10.8 (1)°]. The C atom chain of the hydrogen tartrate ion is in an extended conformation with the hydroxyl O atoms -sc with respect to one another. The hydrogen bonds listed in Table 2 form a three-dimensional network in the crystal.
S2. Experimental
The title compound was obtained from the Janssen Rechearch Foundation, Beerse, Belgium. The synthesis has been described by Heykants et al. (1999). Single crystals were grown by slow evaporation from a solution in methanol–water.
S3. Refinement
supporting information
sup-2
[image:5.610.128.487.68.444.2]Acta Cryst. (2002). E58, o1169–o1171
Figure 1
Perspective view of the title compound with the atomic numbering scheme. Displacement ellipsoids are drawn at the 50% probability level.
(+)-(3S,4R)-cis-4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-1-ium-4-yl) benzamide hydrogen (2R,3R
)-dihydroxybutanedioate monohydrate
Crystal data
C14H21ClN3O3+·C4H5O6−·H2O Mr = 481.89
Monoclinic, P21 a = 7.6086 (4) Å
b = 10.664 (1) Å
c = 14.0482 (6) Å
β = 93.980 (6)°
V = 1137.1 (1) Å3 Z = 2
F(000) = 508
Dx = 1.407 Mg m−3
Cu Kα radiation, λ = 1.54178 Å Cell parameters from 39 reflections
θ = 10.8–28.0°
supporting information
sup-3
Acta Cryst. (2002). E58, o1169–o1171
Data collection
Siemens P4 four-circle diffractometer
ω/2θ scans
Absorption correction: ψ scan (XEMP; Siemens, 1989)
Tmin = 0.325, Tmax = 0.593 2935 measured reflections 2350 independent reflections
2280 reflections with F2 > 2σ(F2) Rint = 0.033
θmax = 69.0°
h = −1→8
k = −1→12
l = −17→17
3 standard reflections every 100 reflections intensity decay: none
Refinement
Refinement on F2
Least-squares matrix: full
R[F2 > 2σ(F2)] = 0.037 wR(F2) = 0.107 S = 1.06 2350 reflections 295 parameters
H-atom parameters constrained
w = 1/[σ2(Fo2) + (0.069P)2 + 0.2043P]
where P = (Fo2 + 2Fc2)/3
(Δ/σ)max < 0.001
Δρmax = 0.21 e Å−3
Δρmin = −0.26 e Å−3
Extinction correction: SHELXL97, Fc*=kFc[1+0.001xFc2λ3/sin((2θ)]-1/4
Extinction coefficient: 0.026 (2)
Absolute structure: Flack (1983), 220 Friedel pairs
Absolute structure parameter: −0.01 (2)
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2)
x y z Uiso*/Ueq
supporting information
sup-4
Acta Cryst. (2002). E58, o1169–o1171
O26 0.4549 (3) 0.2500 (3) 0.5963 (2) 0.0650 (9)* C27 0.4360 (4) 0.4391 (3) 0.6895 (2) 0.0434 (9)* O28 0.4358 (3) 0.5134 (2) 0.6063 (2) 0.0475 (7)* C29 0.2509 (4) 0.4065 (3) 0.7192 (2) 0.047 (1)* O30 0.1244 (3) 0.4570 (3) 0.6666 (2) 0.0628 (8)* O31 0.2339 (3) 0.3397 (4) 0.7876 (2) 0.081 (1)* O32 0.3290 (5) 0.0093 (4) 0.5658 (3) 0.109 (2)* H1A 1.0982 0.8417 0.6244 0.059* H1B 1.0877 0.8485 0.5207 0.059* H2A 0.8349 0.9639 0.5174 0.065* H2B 0.9857 1.0322 0.5795 0.065* H3 0.7268 1.0272 0.6625 0.056* H4 0.6027 0.8395 0.6020 0.055* H5A 0.7224 0.6454 0.6411 0.059* H5B 0.8714 0.7062 0.7088 0.059* H6A 0.9954 0.6549 0.5678 0.064* H6B 0.8449 0.7249 0.5070 0.064* H8A 1.0636 1.0446 0.8347 0.117* H8B 0.8994 1.1179 0.7901 0.117* H8C 1.0592 1.0904 0.7286 0.117* H9 0.6446 0.8589 0.7958 0.064* H14 0.3645 0.9297 1.0536 0.063* H17 0.1398 0.6945 0.7974 0.054* H19A 0.7553 1.0375 0.9779 0.104* H19B 0.6540 0.9551 1.0485 0.104* H19C 0.5655 1.0761 1.0036 0.104* H20A 0.1097 0.8759 1.1359 0.089* H20B −0.0334 0.7957 1.0912 0.089* H25 0.5348 0.2672 0.7312 0.058* H26 0.5276 0.2355 0.5572 0.081* H27 0.4983 0.4851 0.7420 0.054* H28 0.4080 0.5855 0.6188 0.059* H30 0.0299 0.4393 0.6880 0.078* H32A 0.3552 0.0810 0.5891 0.137* H32B 0.3534 0.0097 0.5077 0.137*
Atomic displacement parameters (Å2)
U11 U22 U33 U12 U13 U23
supporting information
sup-5
Acta Cryst. (2002). E58, o1169–o1171
C10 0.037 (2) 0.055 (2) 0.038 (1) 0.003 (1) 0.005 (1) −0.004 (1) O11 0.041 (1) 0.064 (1) 0.041 (1) −0.003 (1) 0.0038 (7) −0.010 (1) C12 0.030 (1) 0.055 (2) 0.040 (1) 0.002 (1) 0.007 (1) −0.003 (1) C13 0.043 (2) 0.056 (2) 0.042 (1) −0.002 (1) 0.007 (1) −0.008 (1) C14 0.048 (2) 0.063 (2) 0.042 (1) −0.001 (2) 0.008 (1) −0.008 (1) C15 0.051 (2) 0.058 (2) 0.041 (1) 0.008 (1) 0.017 (1) 0.005 (1) C16 0.035 (2) 0.059 (2) 0.047 (1) 0.003 (1) 0.011 (1) 0.008 (1) C17 0.035 (2) 0.053 (2) 0.041 (1) 0.002 (1) 0.003 (1) 0.001 (1) O18 0.048 (1) 0.087 (2) 0.050 (1) −0.022 (1) 0.0130 (9) −0.024 (1) C19 0.074 (3) 0.110 (4) 0.066 (2) −0.031 (3) 0.008 (2) −0.035 (3) N20 0.072 (2) 0.093 (2) 0.052 (1) −0.006 (2) 0.032 (1) −0.002 (2) Cl21 0.0483 (5) 0.0927 (7) 0.0693 (5) −0.0162 (4) 0.0172 (3) 0.0086 (5) O22 0.057 (2) 0.111 (2) 0.064 (1) −0.009 (2) 0.032 (1) −0.015 (2) O23 0.029 (1) 0.083 (2) 0.056 (1) −0.003 (1) 0.0063 (8) 0.001 (1) C24 0.030 (1) 0.065 (2) 0.047 (1) 0.003 (1) 0.011 (1) 0.006 (1) C25 0.035 (2) 0.056 (2) 0.049 (2) −0.004 (1) 0.008 (1) 0.001 (1) O26 0.048 (1) 0.069 (2) 0.078 (2) −0.007 (1) 0.004 (1) −0.020 (1) C27 0.031 (2) 0.061 (2) 0.039 (1) −0.006 (1) 0.009 (1) −0.005 (1) O28 0.037 (1) 0.054 (1) 0.053 (1) −0.0037 (9) 0.0135 (8) −0.001 (1) C29 0.028 (1) 0.072 (2) 0.043 (1) −0.001 (1) 0.009 (1) −0.001 (1) O30 0.026 (1) 0.098 (2) 0.065 (1) −0.002 (1) 0.0074 (9) 0.021 (1) O31 0.042 (1) 0.136 (3) 0.067 (1) 0.005 (2) 0.019 (1) 0.039 (2) O32 0.105 (3) 0.072 (2) 0.149 (3) −0.017 (2) 0.000 (2) 0.003 (3)
Geometric parameters (Å, º)
N1—H1A 0.900 C14—H14 0.930
N1—H1B 0.900 C14—C15 1.398 (5)
N1—C2 1.487 (5) C15—C16 1.404 (4)
N1—C6 1.489 (5) C15—N20 1.358 (5)
C2—H2A 0.970 C16—C17 1.384 (4)
C2—H2B 0.970 C16—Cl21 1.735 (3)
C2—C3 1.513 (4) C17—H17 0.930
C3—H3 0.980 O18—C19 1.427 (5)
C3—C4 1.526 (5) C19—H19A 0.960
C3—O7 1.423 (3) C19—H19B 0.960
C4—H4 0.980 C19—H19C 0.960
C4—C5 1.517 (5) N20—H20A 0.860
C4—N9 1.459 (4) N20—H20B 0.860
C5—H5A 0.970 O22—C24 1.242 (4)
C5—H5B 0.970 O23—C24 1.249 (4)
C5—C6 1.527 (5) C24—C25 1.529 (4)
C6—H6A 0.970 C25—H25 0.980
C6—H6B 0.970 C25—O26 1.413 (4)
O7—C8 1.408 (6) C25—C27 1.517 (5)
C8—H8A 0.960 O26—H26 0.820
C8—H8B 0.960 C27—H27 0.980
supporting information
sup-6
Acta Cryst. (2002). E58, o1169–o1171
N9—H9 0.860 C27—C29 1.536 (4)
N9—C10 1.323 (4) O28—H28 0.820
C10—O11 1.254 (3) C29—O30 1.290 (4) C10—C12 1.488 (4) C29—O31 1.210 (5)
C12—C13 1.408 (4) O30—H30 0.820
C12—C17 1.392 (4) O32—H32A 0.850 C13—C14 1.382 (4) O32—H32B 0.850 C13—O18 1.364 (4)
supporting information
sup-7
Acta Cryst. (2002). E58, o1169–o1171
O7—C8—H8C 109.5 C25—C27—C29 109.1 (2) H8A—C8—H8B 109.5 H27—C27—O28 108.3 H8A—C8—H8C 109.5 H27—C27—C29 108.3 H8B—C8—H8C 109.5 O28—C27—C29 113.8 (2) C4—N9—H9 117.3 C27—O28—H28 109.5 C4—N9—C10 125.4 (2) C27—C29—O30 114.3 (2) H9—N9—C10 117.3 C27—C29—O31 120.0 (3) N9—C10—O11 122.0 (3) O30—C29—O31 125.7 (3) N9—C10—C12 118.0 (2) C29—O30—H30 109.5 O11—C10—C12 120.0 (2) H32A—O32—H32B 107.7 C10—C12—C13 126.5 (2)
supporting information
sup-8
Acta Cryst. (2002). E58, o1169–o1171
C2—C3—O7—C8 77.3 (4) C13—O18—C19—H19A 176.4 H3—C3—O7—C8 −44.1 C13—O18—C19—H19B 56.4 C4—C3—O7—C8 −162.6 (3) C13—O18—C19—H19C −63.6 C3—C4—C5—H5A −173.9 O22—C24—C25—H25 115.9 C3—C4—C5—H5B 68.1 O22—C24—C25—O26 −2.4 (4) C3—C4—C5—C6 −52.9 (3) O22—C24—C25—C27 −125.1 (3) H4—C4—C5—H5A −54.1 O23—C24—C25—H25 −62.9 H4—C4—C5—H5B −172.1 O23—C24—C25—O26 178.8 (3) H4—C4—C5—C6 66.9 O23—C24—C25—C27 56.1 (4) N9—C4—C5—H5A 65.8 C24—C25—O26—H26 2.6 N9—C4—C5—H5B −52.1 H25—C25—O26—H26 −115.7 N9—C4—C5—C6 −173.1 (3) C27—C25—O26—H26 125.3 C3—C4—N9—H9 −36.7 C24—C25—C27—H27 −56.2 C3—C4—N9—C10 143.3 (3) C24—C25—C27—O28 61.4 (3) H4—C4—N9—H9 −154.7 C24—C25—C27—C29 −173.9 (3) H4—C4—N9—C10 25.3 H25—C25—C27—H27 62.8 C5—C4—N9—H9 85.3 H25—C25—C27—O28 −179.6 C5—C4—N9—C10 −94.7 (3) H25—C25—C27—C29 −54.9 C4—C5—C6—N1 53.0 (3) O26—C25—C27—H27 −178.1 C4—C5—C6—H6A 173.9 O26—C25—C27—O28 −60.5 (3) C4—C5—C6—H6B −67.9 O26—C25—C27—C29 64.2 (3) H5A—C5—C6—N1 174.0 C25—C27—O28—H28 −164.0 H5A—C5—C6—H6A −65.1 H27—C27—O28—H28 −46.4 H5A—C5—C6—H6B 53.1 C29—C27—O28—H28 74.2 H5B—C5—C6—N1 −68.0 C25—C27—C29—O30 −125.1 (3) H5B—C5—C6—H6A 52.9 C25—C27—C29—O31 55.8 (4) H5B—C5—C6—H6B 171.0 H27—C27—C29—O30 117.2 C3—O7—C8—H8A −178.4 H27—C27—C29—O31 −61.9 C3—O7—C8—H8B 61.6 O28—C27—C29—O30 −3.3 (4) C3—O7—C8—H8C −58.4 O28—C27—C29—O31 177.6 (3) C4—N9—C10—O11 4.3 (5) C27—C29—O30—H30 −176.7 C4—N9—C10—C12 −175.6 (3) O31—C29—O30—H30 2.3
Hydrogen-bond geometry (Å, º)
D—H···A D—H H···A D···A D—H···A
N9—H9···O18 0.86 1.97 2.643 (3) 134 O26—H26···O22 0.82 2.03 2.545 (4) 120 O28—H28···O11 0.82 1.97 2.776 (3) 167 O32—H32A···O26 0.85 1.96 2.764 (5) 158 N1—H1A···O11i 0.90 2.21 2.953 (3) 140
N1—H1B···O22ii 0.90 1.86 2.728 (4) 161
N20—H20A···O23iii 0.86 2.16 2.955 (4) 155
N20—H20B···O31iv 0.86 2.41 2.970 (4) 123
O30—H30···O23v 0.82 1.72 2.535 (3) 171
O32—H32B···O28vi 0.85 2.34 3.107 (5) 150